PharmExec Picks: Having trouble viewing this e-mail? Click here.

Update My Profile | Advertise With Us | Visit PharmExec.com | SUBSCRIBE Pharm Exec Picks is a biweekly eletter that delivers the most popular news and articles from the pharma space and highlights what’s trending on social media. Top 5 Stories : Drug Pricing Backlash Reaches Fever Pitch Doctors, advocates, politicians, and the Feds have jumped on the price-gouging bandwagon. Read more     FDA Looks to Limit Clinical Trials in Biosimilar R&D With one approved biosimilar under its belt, and dozens more under review and in development, FDA's biosimilar development program is moving “beyond the finish line”. But agency officials still have much to do to address critical issues related to product analysis and testing. Read more     Does Interchangeability Really Matter for Biosimilars? The answer is perhaps not that much, according to some biosimilar developers, as well as payers and health plans. Jill Wechsler reports. Read more     Barrier to Generic Competition Threatens Safe, Low Cost Drug Options Carlos Angulo and Alexandra W. “Sasha” Miller argue that an increasingly common brand company tactic is threatening to undermine the entire FDA generic drug approval process. Read more   Sponsored Free White Paper “Hiding in Plain Sight: Copay as the Key to Patient Engagement.” How is our changing healthcare landscape influencing patient affordability programs? Go beyond traditional approaches and see how Pharma is defining program success in the new value-based healthcare landscape. Learn more   Rethinking Product Lifecycle Management "Drug Life Optimization" can wrest more value through strategies that build a drug's brand franchise through its entire lifespan, according to Stan Bernard. Read more   Follow Us   Trending on Social Media : Prix Galien to Highlight Industry Positives The industry's Oscars, the Prix Galien USA Awards will bring red carpet glamor and, hopefully, some cheer to the industry this fall. Read more New Blockbusters Will Push Multiple Myeloma Treatment Market to $22.4 Billion by 2023 The global treatment market for multiple myeloma will rise in value from $8.9 billion in 2014 to an estimated $22.4 billion by 2023, representing CAGR of 11.2%, according to research and consulting firm GlobalData. Read more Improved Access to Patient Data Holds Key to Future Therapies Difficulties in obtaining patient data on the effects of heart failure drugs from previously published clinical trials are making it impossible to assess the outcomes of these drugs on patients, according to an article published yesterday in the BMJ. Read more